AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04674722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Injection of 99mTc-NM-02
Description: A Patient will be injected with microdose (\<100ug) of 99mTc-NM-02 radiotracer
Study NCT04674722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Injection of 188Re-NM-02
Description: A Patient will be injected with microdose (\<100ug) of 188Re-NM-02 radionuclide therapy
Study NCT03864419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV
Study NCT02313584 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dabigatran
Study NCT02313584 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT01636986 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Delefilcon A contact lenses
Description: Silicone hydrogel contact lenses for daily wear, daily disposable use
Study NCT01636986 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Etafilcon A contact lenses
Description: Hydrogel contact lenses for daily wear, daily disposable use
Study NCT03864419 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV
Study NCT01009814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-663068
Description: BMS-663068 will be administered as a tablet formulation
Study NCT01009814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Ritonavir will be administered as a capsule.
Study NCT03095664 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention group
Description: A behavior change program with 4 monthly 90-min sessions about healthy eating and physical activity.
Study NCT01242605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: selumetinib
Description: The starting dose of selumetinib will depend on the cohort. The first dose of selumetinib to be studied will be 75 mg twice daily (bd). Selumetinib will be taken every day (continuously) either once or twice a day, depending on the dose. Treatment with selumetinib may continue until disease progression.
Study NCT03793608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: Dupilumab weight-based dosing will be administered subcutaneously (SC) in a single-use, pre-filled syringe every two weeks (Q2W)
Study NCT03658044 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Participation in the internet forum
Description: Active participation in the forum with encouragement to participate on a weekly basis
Study NCT01242605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: gemcitabine: taken in combination with cisplatin will be given at 1000 mg/m\*2 in 250 - 500 ml 0.9% saline over 30 minutes by intravenous infusion on days 1, and 8 of each 21-day cycle for eight cycles in total
Study NCT01242605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: cisplatin: 25 mg/m\*2 in 1000 ml 0.9% saline given over 1 hour followed by 500mls 0.9% saline over 30 minutes followed by gemcitabine on days 1, and 8 of each 21-day cycle for eight cycles in total
Study NCT03325595 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AEF0117
Description: 0.2, 0.6, 2, or 6mg of AEF0117
Study NCT03325595 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching capsule placebo
Study NCT01195805 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spironolactone
Description: 1 tablet twice a day for 28 days
Study NCT01195805 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 tablet twice a day for 28 days
Study NCT01195805 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amiloride
Description: 1 tablet twice a day for 28 days
Study NCT02498093 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Maximal strength training
Study NCT02498093 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: conventional rehabilitation
Study NCT00286429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alogliptin and insulin
Description: Alogliptin 12.5 mg, tablets, orally, once daily and insulin for up to 26 weeks.
Study NCT00286429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alogliptin and insulin
Description: Alogliptin 25 mg, tablets, orally, once daily and insulin for up to 26 weeks.
Study NCT00286429 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Insulin
Description: Alogliptin placebo-matching tablets, orally, once daily and insulin for up to 26 weeks.
Study NCT02956317 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: STP705
Description: The Cotsiranib drug substance is composed of two siRNA oligonucleotides, targeting TGF-β1 and Cox-2 mRNA respectively, and formulated in nanoparticles with Histidine-Lysine co-Polymer (HKP) peptide at a ratio of 1:4 in mass weight (siRNA:peptide), which is further formulated into a dry powder drug product. The administration route would be intra-dermal injection.
Study NCT02956317 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: STP705
Description: The Cotsiranib drug substance is composed of two siRNA oligonucleotides, targeting TGF-β1 and Cox-2 mRNA respectively, and formulated in nanoparticles with Histidine-Lysine co-Polymer (HKP) peptide at a ratio of 1:4 in mass weight (siRNA:peptide), which is further formulated into a dry powder drug product. The administration route would be intra-dermal injection.
Study NCT02956317 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal Saline
Study NCT02906527 — intervention group
Intervention type: DRUG
Intervention: Non-exposed group
Description: Non-exposed group / Patients receiving VKA
Study NCT02906527 — intervention group
Intervention type: DRUG
Intervention: Exposed group
Description: Exposed group / Patients receiving DOAC
Study NCT02425774 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vagus stimulation
Study NCT02956317 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Normal Saline
Study NCT01756404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin (JNJ-28431754)
Description: A 30mg/day, 100 mg/day, 300 mg/day, or 600 mg/day liquid dose administered once daily; a 300mg/day liquid dose administered in 2 divided doses (2x150 mg); or a 600 mg/day liquid dose administered in 2 divided doses (2x300 mg) using an oral (by mouth) liquid dispenser on Days 1 through 14.
Study NCT01756404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo (inactive medication) liquid dose(s) administered using an oral liquid dispenser once or twice daily on Days 1 through 14.
Study NCT01405612 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Single oral administration on Day 1 or Day 5
Study NCT01405612 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ulimorelin
Description: Intravenous infusion of 480 micrograms/kg on Days 1 to 5
Study NCT00791908 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electrodessication
Description: Treatment applied to a third of the torso at each study visit.
Study NCT00791908 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulsed dye laser (PDL)
Description: Laser treatment applied to a third of the torso at each study visit.
Study NCT00791908 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: potassium titanyl phosphate (KTP)
Description: Laser treatment applied to a third of the torso at each study visit.
Study NCT02926638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib Hydrochloride
Description: Given PO
Study NCT02926638 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erlotinib Hydrochloride
Description: Given PO
Study NCT02926638 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02926638 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02926638 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rilotumumab
Description: Given IV
Study NCT01060852 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Media Detective
Description: 10-lesson elementary school, media literacy education, substance use prevention program. Each lesson takes approximately 45 minutes to teach and was taught every school day for 2 weeks.
Study NCT00952393 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Pharmacokinetic
Description: Subject receives 150 mg of compound formulated with hypomellose and Pharmcokinetics is determined
Study NCT01279603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GO-203-2c
Description: GO-203-2c Injection is a non-preserved, sterile, ready-to-use liquid dosage form provided in a glass vial with rubber closure and crimp seal. Injection will be added to the contents of an intravenous bag (of 0.9% NS, D5W or sterile water) to a final concentration of between 0.03 - 0.3 mg/ml (preferable in 100 mls or greater) and administered as a single agent intravenously over 60 minutes. A treatment cycle will consist of a daily IV dose administered for 21 consecutive days followed by a 7 day rest.
Study NCT01902121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Technosphere® Insulin 10U + 20U
Description: Inhaled Insulin
Study NCT01902121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Technosphere® Insulin 30U
Description: Inhaled Insulin
Study NCT02451514 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenABCWY+OMV vaccine
Description: Intramuscular injection of a single dose at Day 1 to subjects in the MenABCWY+OMV Group or as a 2 doses at Day 1 and Day 31, one month apart, to subjects in the MenACWY and Naive Groups.
Study NCT02536924 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Waiting Room Intervention
Description: The waiting room intervention is called RESOLVE (Relaxation SOLving problem and cognitive errors), which is a short film.
Study NCT02536924 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment as usual.
Description: The patient will receive treatment as usual.
Study NCT03658044 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: No intervention performed. Patients are offered to read the open pages on the website
Study NCT04544774 — intervention group
Intervention type: DRUG
Intervention: AIT
Description: AIT for airborn allergens (SCIT/SLIT)
Study NCT04544774 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: NAPT
Description: NAPT test with airborn allergens ( HDM, Threes, Grasses)
Study NCT02425774 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sham stimulation
Study NCT02425774 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Sham stimulation
Study NCT02425774 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prucalopride
Study NCT02425774 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04259112 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: high pressure
Description: High-pressure pneumoperitoneum is defined as intra-abdominal pressure 12-15 mmHg.
Study NCT04259112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: deep neuromuscular block
Description: Deep neuromuscular block is defined as PTC 1-2.
Study NCT04259112 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: low pressure
Description: Low-pressure pneumoperitoneum is defined as intra-abdominal pressure 7-10 mmHg.
Study NCT04259112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: moderate neuromuscular block
Description: Moderate neuromuscular block is defined as TOF twitch 1-2.
Study NCT02550327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: 125 mg/m2
Study NCT02550327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000 mg/m2
Study NCT02550327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 25 mg/m2
Study NCT02550327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra
Description: 100 mg
Study NCT04916184 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: aerobic exercise
Description: exercise training rehabilitation (aerobic exercise with/without strength training)
Study NCT04916184 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: combined exercise
Description: exercise training rehabilitation (aerobic exercise with/without strength training)
Study NCT02649881 — intervention group
Intervention type: PROCEDURE
Intervention: The heart subject will undergo OCT
Study NCT03412916 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GetActive
Description: GetActive is a comprehensive, multimodal treatment that was designed to increase quality of life, resiliency and ability to cope with medical symptoms and stress. This program is rooted in the elicitation of the relaxation response, a non-judgmental state of focused attention and increased awareness.
Study NCT03412916 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Get Active with Fitbit
Description: The GetActive Program for Pain with a Digital Monitoring Device (GetActive Fitbit) is identical to the GetActive with the addition of a FitBit for recording of physical activity.
Study NCT02311465 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Palliative Care
Description: Components of the palliative care service intervention are expected to include:~* Establishment of a palliative care plan~* Care coordination by palliative care team~* Informational, patient friendly materials supporting Palliative Care~* Communication by palliative care team to all providers and teams involved in patient's care~* Systematic collection of information, including identification of surrogate or health care proxy and advance care planning~* Questionnaires capturing health related quality of life at regular intervals throughout the intervention period
Study NCT03696654 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: adenotonsillar surgery
Description: when indicated, adenotonsillar surgery for SDB treatment
Study NCT04270981 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-acoziborole capsule, 240 mg containing NMT 9.25 kBq (250 nCi) 14C
Description: 960 mg (4 × 240 mg capsules)of acoziborole in oral and fasted condition
Study NCT02450214 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Saline
Description: 50 mL syringe will be infused at 0.3 mL/Kg in bolus and then 0.15 mL/Kg/h 100 mL flask will be infused at 1mL/Kg in bolus for 30 min and then 0.25mL/Kg/h
Study NCT02450214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: 50 mL syringe will be infused at 0.3 mL/Kg in bolus and then 0.15 mL/Kg/h 100 mL flask will be infused at 1mL/Kg in bolus for 30 min and then 0.25mL/Kg/h
Study NCT02450214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine + magnesium
Description: 50 mL syringe will be infused at 0.3 mL/Kg in bolus and then 0.15 mL/Kg/h 100 mL flask will be infused at 1mL/Kg in bolus for 30 min and then 0.25mL/Kg/h
Study NCT03650907 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group exercise program
Description: Patients in experimental group attend group exercise program, instructed by fitness trainer, at long-term care institutions.~Frequency: 3 times per week. Type: resistance/flexibility/balance training, including warm-up and cold-down. Duration: 1 hour per time, for 16 weeks.
Study NCT03650907 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Self exercise program
Description: Patients in control group receive oral education for self exercise program, mainly resistance muscle training. Patients are requested to do self-training for 16 weeks.
Study NCT02619890 — intervention group
Intervention type: OTHER
Intervention: Brain Glioma Registry
Study NCT01387321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BYL719
Study NCT03898765 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Dry blood spot screening
Description: Dry blood spot measurement of biomarker for screening biliary atresia
Study NCT00646412 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: A-Part® Gel
Description: 10 - 20 ml of A-Part® Gel will be administered before abdominal wall closure in a standardised fashion
Study NCT04256616 — intervention group
Intervention type: OTHER
Intervention: This is an observational study that does not concern a direct intervention on patients and control subjects and does not interfere with the clinical management of patients.
Description: urine collection: DNA is isolated from urine samples (catheterized, washout, midstream) and the 16S rRNA gene is sequenced.~Specimen collection: Specimens collected during TURBT are selected by a pathologist and trasferred to the laboratory. The tissues are treated ex vivo with MMC.
Study NCT00888303 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: 20 minutes before total or partial thyroidectomy for benign disease a single dose of intravenous 8 mg/2mL of dexamethasone is administered
Study NCT00888303 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline solution
Description: 20 minutes before total or partial thyroidectomy for benign disease 100 mg of saline solutions are administered intravenous
Study NCT00888303 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thyroidectomy, total or partial
Description: Surgical standard intervention
Study NCT00888303 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Thyroidectomy, total or partial
Description: Surgical standard intervention
Study NCT04275128 — intervention group
Intervention type: DEVICE
Intervention: Cooled radiofrequency ablation
Description: Cooled radiofrequency thermal treatment uses the electrical current produced by radio waves to destroy a part of nerve tissue and relieve pain.
Study NCT02425774 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study NCT01801475 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Description: Pregnant \& non-pregnant women will receive either 4mg or 8mg of Ondansetron (IV) once prior to surgical procedure (open-label). Women are in the study for 8 hours. Babies of pregnant women are not given Ondansetron but are in the study for 24-48 hours.
Study NCT00717899 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Spirometry (Pony spirometer)
Description: Spirometry at rest
Study NCT00994045 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fibrinogen concentrate
Description: Fibrinogen concentrate will be administered initially at 2 grammes per hour by continuous infusion. This rate will be adjusted in response to the clinical picture and results of point of care coagulation tests. The infusion will be used intra-operatively.
Study NCT00994045 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fresh Frozen Plasma
Study NCT01302366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TBL12
Study NCT00822185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vatreptacog alfa (activated)
Description: One single dose is injected i.v. over 2 minutes to 6 subjects, 5 mcg/kg
Study NCT00822185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vatreptacog alfa (activated)
Description: One single dose is injected i.v. over 2 minutes to 6 subjects, 10 mcg/kg
Study NCT00822185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vatreptacog alfa (activated)
Description: One single dose is injected i.v. over 2 minutes to 6 subjects, 20 mcg/kg
Study NCT00822185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vatreptacog alfa (activated)
Description: One single dose is injected i.v. over 2 minutes to 6 subjects, 30 mcg/kg
Study NCT04275128 — intervention group
Intervention type: DEVICE
Intervention: Conventional radiofrequency ablation
Description: Genicular nerve ablation involves using radiofrequency to heat up the genicular nerve until it dies, causing relief of pain. This is a minimally invasive treatment that does not require any medication.
Study NCT03711162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG1690
Description: GLPG1690, film-coated tablets for oral use.
Study NCT03711162 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo, film-coated tablets for oral use.
Study NCT02888847 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Philips Zoom! White Speed whitening lamp
Description: bleaching protocol with descending built in light intensities
Study NCT02888847 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Philips Zoom! Advanced power whitening lamp
Description: bleaching protocol with high light intensity
Study NCT02795390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chinese herbal medicine
Study NCT02795390 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02009410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Creon
Description: Creon 25000 (2 capsules per meal 3 times per day and 1 capsule/snack 2 times per day) during 12 weeks